Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONTAIN
DRKS00031059Phase 2Completed
- Sponsor
- URSAPHARM
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Azelastine 0.1% nasal spray with Placebo nasal spray (2 arms). Started Jan 2023; status: completed.
02
Drugs
azelastine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on DRKS00031059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00031059.